false000092129900009212992024-09-272024-09-270000921299dei:FormerAddressMember2024-09-272024-09-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2024

 

 

FIBROGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36740

77-0357827

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 Bay Street

Suite 100 #6009

 

San Francisco, California

 

94133

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 978-1200

 

FibroGen, Inc.

409 Illinois Street

San Francisco, California 94158

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

FGEN

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.02 Termination of a Material Definitive Agreement.

As part of the continuing efforts of FibroGen, Inc. (“FibroGen”) to reduce operating expenses and preserve cash, on September 27, 2024, FibroGen entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises ("Lease Termination Agreement") with its landlord, ARE-San Francisco No.43 Owner, LLC ("ARE") related to the premises located at 409 Illinois Street, San Francisco, California 94158. The Lease Termination Agreement modifies the Lease Agreement dated as of September 22, 2006, as subsequently amended (the "Lease") and accelerates the expiration date of the term of the Lease to December 31, 2024.

In consideration of the Lease Termination Agreement, FibroGen and ARE agreed on a $10 million settlement amount, consisting of (1) a one-time cash payment by FibroGen for past rent, FibroGen’s share of operating costs, taxes, insurance, utilities, and other costs, and a Lease modification payment, and (2) a security deposit, in the form of a letter of credit.

As of execution of this Lease Termination Agreement, FibroGen shall not be responsible for the payment of any further rent payments or operating costs, taxes, insurance, utilities, or any other scheduled monthly payments due under the Lease to ARE.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

FIBROGEN, INC.

 

 

 

 

Date:

October 3, 2024

By:

/s/ Michael Lowenstein

 

 

 

Michael Lowenstein
Chief Legal Officer

 

v3.24.3
Document And Entity Information
Sep. 27, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 27, 2024
Entity Registrant Name FIBROGEN, INC.
Entity Central Index Key 0000921299
Entity Emerging Growth Company false
Entity File Number 001-36740
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 77-0357827
Entity Address, Address Line One 350 Bay Street
Entity Address, Address Line Two Suite 100 #6009
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94133
City Area Code 415
Local Phone Number 978-1200
Entity Information, Former Legal or Registered Name FibroGen, Inc.
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol FGEN
Security Exchange Name NASDAQ
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 409 Illinois Street
Entity Address, City or Town San Francisco,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more FibroGen Charts.
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more FibroGen Charts.